Profusa, Inc. (PFSA) stock
Close on Nov 11, 2026Market cap $72.77KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $72.77K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$42.97M
- EPS, diluted
- -$107.01
- Free cash flow
- -$16.26M
- Book value per share
- -$470.33
- Diluted shares
- 0M
Trading
- Previous close
- $0.55
- Open
- $0.54
- Day's range
- $0.53 – $0.65
- Volume
- 702,295
- Average volume (20 days)
- 2,679,573
- Beta (5 years)
- 0.46
- 52-week range
- $0.51 – $1594.15
- RSI (14 days)
- 34.0
- Volatility (1 year)
- 566.5%
- Relative volume
- 0.28×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PFSA | S&P 500 | Difference | PFSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -61.3% | -2.4% | −58.9 pts | ||
| 3 months | -86.0% | -1.2% | −84.9 pts | ||
| Year to date | -99.9% | +12.3% | −112.2 pts | ||
| 1 year | -100.0% | +12.4% | −112.4 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -98.1% | +21.4% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Profusa filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- Update
- Update
- News
About Profusa
Surgical & Medical Instruments & Apparatus
Profusa, Inc. is a digital health technology company developing a continuous biochemical sensor platform for monitoring individual biochemistry in real time. The platform integrates passive, subcutaneous hydrogel biosensors with wearable, rechargeable optical readers and mobile data algorithms to track physiological biomarkers. Its lead product candidates include Lumee Oxygen, designed to monitor dissolved tissue oxygen for managing wound care and peripheral arterial disease in critical limb ischemia patients, and Lumee Glucose, a continuous glucose monitoring platform designed for individuals with diabetes. The technology serves patients and healthcare professionals in clinical, surgical, and ambulatory settings.
Company profile, executives and historyProfusa stock: common questions
What is Profusa's stock price?
PFSA closed at $0.55 on Nov 11, 2026, up 0.18% on the day. Over the past 52 weeks it traded between $0.51 and $1594.15.
What is Profusa's market cap?
Profusa was worth $72.77K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PFSA's P/E ratio?
Profusa lost money over fiscal 2025 (diluted EPS -$107.01), so it has no meaningful P/E ratio.
Does Profusa pay a dividend?
No. Profusa has not paid a cash dividend over the last twelve months.
How has PFSA stock performed over the past year?
Including dividends, PFSA returned -100.0% over the past year, against +12.4% for the S&P 500.
Who are Profusa's competitors?
Companies most similar to Profusa by business, industry and size include GUTS, PAVM, RDGL, GIPL, QTEX.
See a number that looks wrong?